DOI QR코드

DOI QR Code

Clinical features and outcomes of systemic amyloidosis with gastrointestinal involvement: a single-center experience

  • Lim, A Young (Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Lee, Ji Hyeon (Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Jung, Ki Sun (Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Gwag, Hye Bin (Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Kim, Do Hee (Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Kim, Seok Jin (Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Lee, Ga Yeon (Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Kim, Jung Sun (Department of Pathology, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Kim, Hee-Jin (Department of Laboratory Medicine & Genetics, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Lee, Soo-Youn (Department of Laboratory Medicine & Genetics, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Lee, Jung Eun (Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Jeon, Eun-Seok (Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Kim, Kihyun (Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine)
  • Received : 2014.07.25
  • Accepted : 2014.10.10
  • Published : 2015.07.01

Abstract

Background/Aims: The gastrointestinal (GI) tract often becomes involved in patients with systemic amyloidosis. As few GI amyloidosis data have been reported, we describe the clinical features and outcomes of patients with pathologically proven GI amyloidosis. Methods: We identified 155 patients diagnosed with systemic amyloidosis between April 1995 and April 2013. Twenty-four patients (15.5%) were diagnosed with GI amyloidosis using associated symptoms, and the diagnoses were confirmed by direct biopsy. Results: Among the 24 patients, 20 (83.3%) had amyloidosis light chain (AL), three (12.5%) had amyloid A, and one (4.2%) had transthyretin-related type amyloidosis. Their median age was 57 years (range, 37 to 72), and 10 patients were female (41.7%). The most common symptoms of GI amyloidosis were diarrhea (11 patients, 45.8%), followed by anorexia (nine patients, 37.5%), weight loss, and nausea and/or vomiting (seven patients, 29.2%). The histologically confirmed GI tract site in AL amyloidosis was the stomach in 11 patients (55.0%), the colon in nine (45.0%), the rectum in seven (35.0%), and the small bowel in one (5.0%). Patients with GI involvement had a greater frequency of organ involvement (p = 0.014). Median overall survival (OS) in patients with GI involvement was shorter (7.95 months; range, 0.3 to 40.54) than in those without GI involvement (15.84 months; range, 0.0 to 114.53; p = 0.069) in a univariate analysis. A multivariate analysis of prognostic factors for AL amyloidosis revealed that GI involvement was not a significant predictor of OS (p = 0.447). Conclusions: The prognosis of patients with AL amyloidosis and GI involvement was poorer than those without GI involvement, and they presented with more organ involvement and more advanced disease than those without organ involvement.

Keywords

Acknowledgement

Supported by : Ministry of Health and Welfare

References

  1. Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med 2003;349:583-596. https://doi.org/10.1056/NEJMra023144
  2. Ebert EC, Nagar M. Gastrointestinal manifestations of amyloidosis. Am J Gastroenterol 2008;103:776-787. https://doi.org/10.1111/j.1572-0241.2007.01669.x
  3. Falk RH, Comenzo RL, Skinner M. The systemic amyloidoses. N Engl J Med 1997;337:898-909. https://doi.org/10.1056/NEJM199709253371306
  4. Lachmann HJ, Goodman HJ, Gilbertson JA, et al. Natural history and outcome in systemic AA amyloidosis. N Engl J Med 2007;356:2361-2371. https://doi.org/10.1056/NEJMoa070265
  5. Petre S, Shah IA, Gilani N. Review article: gastrointestinal amyloidosis: clinical features, diagnosis and therapy. Aliment Pharmacol Ther 2008;27:1006-1016. https://doi.org/10.1111/j.1365-2036.2008.03682.x
  6. Sipe JD, Benson MD, Buxbaum JN, et al. Amyloid fibril protein nomenclature: 2012 recommendations from the Nomenclature Committee of the International Society of Amyloidosis. Amyloid 2012;19:167-170. https://doi.org/10.3109/13506129.2012.734345
  7. Cowan AJ, Skinner M, Seldin DC, et al. Amyloidosis of the gastrointestinal tract: a 13-year, single-center, referral experience. Haematologica 2013;98:141-146. https://doi.org/10.3324/haematol.2012.068155
  8. Madsen LG, Gimsing P, Schiodt FV. Primary (AL) amyloidosis with gastrointestinal involvement. Scand J Gastroenterol 2009;44:708-711.
  9. Gertz MA, Comenzo R, Falk RH, et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. Am J Hematol 2005;79:319-328. https://doi.org/10.1002/ajh.20381
  10. Tada S, Iida M, Iwashita A, et al. Endoscopic and biopsy findings of the upper digestive tract in patients with amyloidosis. Gastrointest Endosc 1990;36:10-14. https://doi.org/10.1016/S0016-5107(90)70913-3
  11. Tada S. Diagnosis of gastrointestinal amyloidosis with special reference to the relationship with amyloid fibril protein. Fukuoka Igaku Zasshi 1991;82:624-647.
  12. Hayman SR, Lacy MQ, Kyle RA, Gertz MA. Primary systemic amyloidosis: a cause of malabsorption syndrome. Am J Med 2001;111:535-540. https://doi.org/10.1016/S0002-9343(01)00919-6
  13. Obici L, Perfetti V, Palladini G, Moratti R, Merlini G. Clinical aspects of systemic amyloid diseases. Biochim Biophys Acta 2005;1753:11-22. https://doi.org/10.1016/j.bbapap.2005.08.014
  14. Menke DM, Kyle RA, Fleming CR, Wolfe JT 3rd, Kurtin PJ, Oldenburg WA. Symptomatic gastric amyloidosis in patients with primary systemic amyloidosis. Mayo Clin Proc 1993;68:763-767. https://doi.org/10.1016/S0025-6196(12)60634-X
  15. James DG, Zuckerman GR, Sayuk GS, Wang HL, Prakash C. Clinical recognition of Al type amyloidosis of the luminal gastrointestinal tract. Clin Gastroenterol Hepatol 2007;5:582-588. https://doi.org/10.1016/j.cgh.2007.02.038
  16. Gould M, Zarrin-Khameh N, Sellin J. Small bowel amyloidosis. Curr Gastroenterol Rep 2013;15:350. https://doi.org/10.1007/s11894-013-0350-4
  17. Kumar S, Dispenzieri A, Lacy MQ, et al. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol 2012;30:989-995. https://doi.org/10.1200/JCO.2011.38.5724
  18. Gertz MA. Immunoglobulin light chain amyloidosis: 2013 update on diagnosis, prognosis, and treatment. Am J Hematol 2013;88:416-425. https://doi.org/10.1002/ajh.23400
  19. Kourelis TV, Kumar SK, Gertz MA, et al. Coexistent multiple myeloma or increased bone marrow plasma cells define equally high-risk populations in patients with immunoglobulin light chain amyloidosis. J Clin Oncol 2013;31:4319-4324. https://doi.org/10.1200/JCO.2013.50.8499
  20. Desikan KR, Dhodapkar MV, Hough A, et al. Incidence and impact of light chain associated (AL) amyloidosis on the prognosis of patients with multiple myeloma treated with autologous transplantation. Leuk Lymphoma 1997;27:315-319. https://doi.org/10.3109/10428199709059685
  21. Dember LM. Amyloidosis-associated kidney disease. J Am Soc Nephrol 2006;17:3458-3471. https://doi.org/10.1681/ASN.2006050460

Cited by

  1. Amyloidosis of the gastrointestinal tract and the liver: clinical context, diagnosis and management vol.28, pp.10, 2015, https://doi.org/10.1097/meg.0000000000000695
  2. Periorbital Ecchymosis (Raccoon Eye) and Orbital Hematoma following Endoscopic Retrograde Cholangiopancreatography vol.11, pp.1, 2015, https://doi.org/10.1159/000456657
  3. Gastrointestinal Amyloidosis: Review of the Literature vol.9, pp.5, 2017, https://doi.org/10.7759/cureus.1228
  4. Case report and review of the literature of primary gastrointestinal amyloidosis diagnosed with enteroscopy and endoscopic ultrasonography vol.6, pp.9, 2015, https://doi.org/10.12998/wjcc.v6.i9.284
  5. Small Bowel Amyloidosis vol.20, pp.3, 2015, https://doi.org/10.1007/s11894-018-0616-y
  6. Clinical implications of gastrointestinal symptoms in systemic amyloidosis vol.30, pp.4, 2015, https://doi.org/10.1111/nmo.13229
  7. Localized Gastric Amyloidosis with Kappa and Lambda Light Chain Co-Expression vol.51, pp.3, 2015, https://doi.org/10.5946/ce.2017.118
  8. A Case of Amyloidosis Presenting as Lymphadenopathy at the Porta Hepatis vol.18, pp.3, 2015, https://doi.org/10.7704/kjhugr.2018.18.3.209
  9. Symptomatic involvement of the stomach and duodenum as initial presentation of AL amyloidosis vol.12, pp.1, 2015, https://doi.org/10.1136/bcr-2018-227550
  10. Gastrointestinal manifestations of amyloidosis vol.27, pp.4, 2015, https://doi.org/10.11569/wcjd.v27.i4.260
  11. Prevalence of digestive manifestations in patients with amyloidosis vol.26, pp.suppl1, 2015, https://doi.org/10.1080/13506129.2019.1582492
  12. Chronic intestinal pseudo-obstruction due to al amyloidosis: a case report and literature review vol.12, pp.2, 2015, https://doi.org/10.1007/s12328-018-0909-6
  13. Fatal refractory cardiac arrest as presentation of systemic amyloidosis vol.30, pp.None, 2020, https://doi.org/10.1016/j.rmcr.2020.101042
  14. Primary Localized Amyloidosis of the Intestine: A Pathologist Viewpoint vol.13, pp.4, 2020, https://doi.org/10.14740/gr1303
  15. Curious case of gut dysmotility vol.70, pp.1, 2021, https://doi.org/10.1136/gutjnl-2019-319840
  16. Outcome of patients with severe AL amyloidosis and biopsy-proven renal involvement ineligible for bone marrow transplantation vol.34, pp.1, 2015, https://doi.org/10.1007/s40620-020-00748-7
  17. Small and Large Intestine (I): Malabsorption of Nutrients vol.13, pp.4, 2015, https://doi.org/10.3390/nu13041254
  18. Suggestive Diagnostic Process in a Case of Multiple Myeloma with Gastrointestinal Immunoglobulin Light-Chain Amyloidosis Accompanied by Protein-Losing Enteropathy vol.2021, pp.None, 2015, https://doi.org/10.1155/2021/5533993
  19. Diseases which cause generalized peripheral neuropathy: a systematic review vol.56, pp.9, 2021, https://doi.org/10.1080/00365521.2021.1942542